IS5270A - (R)-3-N,N-dísýklóbútýlamínó-8-flúor-3,4-díhýdró-2H-1-bensópýran-5-karboxamíðhýdrógentartrat, aðferðvið framleiðslu þess og lyfjablöndur sem innihalda það - Google Patents

(R)-3-N,N-dísýklóbútýlamínó-8-flúor-3,4-díhýdró-2H-1-bensópýran-5-karboxamíðhýdrógentartrat, aðferðvið framleiðslu þess og lyfjablöndur sem innihalda það

Info

Publication number
IS5270A
IS5270A IS5270A IS5270A IS5270A IS 5270 A IS5270 A IS 5270A IS 5270 A IS5270 A IS 5270A IS 5270 A IS5270 A IS 5270A IS 5270 A IS5270 A IS 5270A
Authority
IS
Iceland
Prior art keywords
dicyclobutylamino
benzopyran
dihydro
fluoro
pharmaceutical preparations
Prior art date
Application number
IS5270A
Other languages
English (en)
Other versions
IS1943B (is
Inventor
Nyqvist Håkan
D. Sohn Daniel
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of IS5270A publication Critical patent/IS5270A/is
Publication of IS1943B publication Critical patent/IS1943B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
IS5270A 1997-05-30 1999-11-24 (R)-3-N,N-dísýklóbútýlamínó-8-flúor-3,4-díhýdró-2H-1-bensópýran-5-karboxamíðhýdrógentartrat, aðferðvið framleiðslu þess og lyfjablöndur sem innihalda það IS1943B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702066A SE510305C2 (sv) 1997-05-30 1997-05-30 Nytt salt
PCT/SE1998/000907 WO1998054166A1 (en) 1997-05-30 1998-05-15 A new salt

Publications (2)

Publication Number Publication Date
IS5270A true IS5270A (is) 1999-11-24
IS1943B IS1943B (is) 2004-08-13

Family

ID=20407187

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5270A IS1943B (is) 1997-05-30 1999-11-24 (R)-3-N,N-dísýklóbútýlamínó-8-flúor-3,4-díhýdró-2H-1-bensópýran-5-karboxamíðhýdrógentartrat, aðferðvið framleiðslu þess og lyfjablöndur sem innihalda það

Country Status (33)

Country Link
US (2) US6858645B2 (is)
EP (1) EP0984952B1 (is)
JP (1) JP3554338B2 (is)
KR (1) KR20010013127A (is)
CN (1) CN1198814C (is)
AR (1) AR012751A1 (is)
AT (1) ATE228121T1 (is)
AU (1) AU729301B2 (is)
BG (1) BG64051B1 (is)
BR (1) BR9809519A (is)
CA (1) CA2291732C (is)
DE (1) DE69809547T2 (is)
DK (1) DK0984952T3 (is)
EE (1) EE03874B1 (is)
ES (1) ES2187030T3 (is)
HU (1) HUP0001878A3 (is)
ID (1) ID23794A (is)
IL (1) IL133234A (is)
IS (1) IS1943B (is)
MY (1) MY117960A (is)
NO (1) NO995853L (is)
NZ (1) NZ501075A (is)
PL (1) PL337181A1 (is)
PT (1) PT984952E (is)
RU (1) RU2193560C2 (is)
SE (1) SE510305C2 (is)
SK (1) SK282755B6 (is)
TR (1) TR199902926T2 (is)
TW (1) TW510899B (is)
UA (1) UA53720C2 (is)
WO (1) WO1998054166A1 (is)
YU (1) YU62499A (is)
ZA (1) ZA984486B (is)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102886D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102888D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
JP2006500366A (ja) * 2002-08-15 2006-01-05 ワイス 温度調節機能障害の治療ための５ＨＴ２ａ受容体の拮抗
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
ATE528807T1 (de) * 2006-05-11 2011-10-15 Johnson Controls Saft Advanced Power Solutions Llc Modulares batteriesystem
JP5163931B2 (ja) * 2007-03-08 2013-03-13 株式会社リコー 定着装置及び画像形成装置
EP2065385A1 (en) * 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
CN103833713B (zh) * 2008-11-28 2016-02-03 中国医学科学院药物研究所 硝克柳胺化合物晶iii型、其制法和其药物组合物与用途
US9637479B2 (en) * 2013-04-26 2017-05-02 Sanofi Tartrate salt of 5-chloro-thiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxo-pyrrolidin-1-yl)-benzenesulfonylamino]-3-(4-methyl-piperazin-1-yl)-3-oxo-propyl]amide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU611976B2 (en) * 1987-12-24 1991-06-27 John Wyeth & Brother Limited Aroyl urea and carbamic acid derivatives of azabicyclo compounds
US5616610A (en) * 1989-12-22 1997-04-01 Astra Aktiebolag (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
US5420151A (en) 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
RU2047614C1 (ru) * 1992-06-15 1995-11-10 Джон Вайс энд Бразер Лимитед Гетероциклические соединения, или их фармацевтически приемлемые аддитивные соли кислоты, или n-оксид гетероциклического соединения, или его аддитивная соль кислоты
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
IT1282705B1 (it) 1996-02-28 1998-03-31 Recordati Chem Pharm Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria

Also Published As

Publication number Publication date
AU7792398A (en) 1998-12-30
ID23794A (id) 2000-05-11
CA2291732C (en) 2003-12-30
BG103949A (en) 2000-07-31
MY117960A (en) 2004-08-30
DE69809547T2 (de) 2003-08-21
NZ501075A (en) 2001-08-31
US20050085532A1 (en) 2005-04-21
BR9809519A (pt) 2000-06-20
CA2291732A1 (en) 1998-12-03
TW510899B (en) 2002-11-21
ES2187030T3 (es) 2003-05-16
AU729301B2 (en) 2001-02-01
CN1258290A (zh) 2000-06-28
HUP0001878A3 (en) 2002-04-29
DK0984952T3 (da) 2003-02-24
TR199902926T2 (xx) 2000-03-21
ZA984486B (en) 1998-11-30
IL133234A (en) 2004-05-12
PL337181A1 (en) 2000-08-14
KR20010013127A (ko) 2001-02-26
DE69809547D1 (de) 2003-01-02
EE03874B1 (et) 2002-10-15
EP0984952B1 (en) 2002-11-20
EE9900549A (et) 2000-06-15
US6858645B2 (en) 2005-02-22
SE510305C2 (sv) 1999-05-10
IL133234A0 (en) 2001-03-19
SK282755B6 (sk) 2002-12-03
PT984952E (pt) 2003-03-31
JP2002501527A (ja) 2002-01-15
BG64051B1 (bg) 2003-11-28
JP3554338B2 (ja) 2004-08-18
AR012751A1 (es) 2000-11-08
HUP0001878A2 (hu) 2001-05-28
EP0984952A1 (en) 2000-03-15
RU2193560C2 (ru) 2002-11-27
SK159499A3 (en) 2000-10-09
SE9702066D0 (sv) 1997-05-30
UA53720C2 (uk) 2003-02-17
ATE228121T1 (de) 2002-12-15
SE9702066L (sv) 1998-12-01
IS1943B (is) 2004-08-13
YU62499A (sh) 2002-06-19
NO995853D0 (no) 1999-11-29
US20030109576A1 (en) 2003-06-12
NO995853L (no) 2000-01-31
WO1998054166A1 (en) 1998-12-03
CN1198814C (zh) 2005-04-27
HK1025575A1 (en) 2000-11-17

Similar Documents

Publication Publication Date Title
IS5409A (is) Útskipt karboxamídóþíasól, framleiðsla þeirra og lyfjablöndur sem innihalda þau
HUP0103793A3 (en) N-(2-aryl-propionyl)-sulfonamids, their use and pharmaceutical preparations containing them
HUP0204519A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing them and process for their preparations
NO20005430D0 (no) 1-[(1-substituerte-4-piperidinyl)metyl]-4-piperidinderivater, fremgangsmÕter for fremstilling av disse, medisinske preparater inneholdende dem, og mellomprodukter
NO953260D0 (no) Glycinamid-derivater, fremgangsmåter for fremstilling derav og medisiner som inneholder dem
HUP0003608A3 (en) Tetrahydroisoquinoline derivatives, process for producing them and pharmaceutical compositions containing them
IS2076B (is) Asýl-píperasínil-pýrimídínafleiður, framleiðsla og notkun þeirra sem lyfja
PL344346A1 (en) Platinum complex, its preparation and therapeutic application
DK1071433T3 (da) 2',2'-difluornucleosider til immunosuppressiv behandling og kombinationspræparater
HUP0000762A3 (en) 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines, and pharmaceutical compositions containing them
GB2322568B (en) Gas treatment devices
NO20002181D0 (no) Steriliseringsinnpakning, anvendelse derav og fremgangsmÕte for sterilisering
NO20003662D0 (no) Syntetiske polysakkarider, fremgangsmÕte for fremstilling derav og farmasøytiske preparater inneholdende slike
IS5270A (is) (R)-3-N,N-dísýklóbútýlamínó-8-flúor-3,4-díhýdró-2H-1-bensópýran-5-karboxamíðhýdrógentartrat, aðferðvið framleiðslu þess og lyfjablöndur sem innihalda það
HUP9802408A3 (en) Naphthyl and dihydronaphthyl-derivatives, and pharmaceutical compositions, containing them
HUP0100964A3 (en) Pharmaceutical combinations containing tramadol
DK1054672T3 (da) Morfinsulfatmikrogranula, fremgangsmåde til fremstilling deraf og farmaceutiske præparater
DK0795547T3 (da) (Aminoalkyl- og acylaminoalkyl-oxy)benzyloxyquinoliner, fremgangsmåde til deres fremstilling og deres anvendelse som bradyk
NO975076D0 (no) Farmasöytisk preparat som inneholder tiagabinhydroklorid, og fremgangsmåte for dets fremstilling
NO960272L (no) Oksatiolaner, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder de samme
PL335089A1 (en) Pharmaceutic preparations for treating henicrania, containing ibuprofen and domperidone
NO20001288L (no) Substituerte 1,2,3,4,5,6-heksahydro-2,6-metano-3-benzazocin- 10-oler, fremgangsmõte for fremstilling derav og anvendelse som legemiddel
PL344345A1 (en) Platinum complex, its preparation and therapeutic application
NO20014803D0 (no) Pyrido-tieno-diazepiner, fremgangsmåte for fremstilling derav og farmasöytiske blandinger inneholdende dem
DK1053224T3 (da) Biphenylfulfonylcyanamider, fremgangsmåde til fremstilling deraf og anvendelse deraf som lægemiddel